Practice makes perfect: Reflections on a primary care treatment-to-target study

International Journal of Clinical Practice

Volumn 64, Issue 8, 2010, Pages 1006-1008

  Wierzbicki, A S ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE;

EID: 77953813816     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02459.x     Document Type: Editorial

References (21)

1. McCormack T, Harvey P, Gaunt R et al. Incremental cholesterol reduction with simvastatin-ezetimibe, atorvastatin and rosuvastatin in UK general practice (IN-PRACTICE). Randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010 64 : 1052 1061.
2. British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005 91 (Suppl. 4 51 52.
3. Minhas R. Eminence-based guidelines: a quality assessment of the second Joint British Societies' guidelines on the prevention of cardiovascular disease. Int J Clin Pract 2007 61 : 1137 1144.
4. National Institute for Health and Clinical Excellence. Lipid Modification.
5. Wierzbicki AS. SEARCHing for JUPITER: starry eyed optimism is not warranted. Int J Clin Pract 2009 63 : 685 688.
6. Food & Drug Administration. FDA Drug Safety Communication: Ongoing Safety Review of High-Dose Zocor (Simvastatin) and Increased Risk of Muscle Injury.
7. National Institute for Health and Clinical Excellence. Type 2 Diabetes: The Management of Type 2 Diabetes (Update).
8. National Institute for Health and Clinical Excellence. Ezetimibe for the Treatment of Primary (Heterozygous-Familial and non-Familial) Hypercholesterolaemia: Technology Appraisal 132.
9. Fowkes FG, Price JF, Stewart MC et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010 303 : 841 848.
10. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 2207.
11. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001 344 : 1959 1965.
12. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 2008 62 : 981 987.
13. * Trial). Am J Cardiol 2003 92 : 152 160.
14. Crouse JR III., Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 297 : 1344 1353.
15. Medicines & Health Regulatory Agency. Statins: interactions and updated advice for atorvastatin. Drug Safety Update 2008 1 : 2 5.
16. Ara R, Rafia R, Ward SE et al. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? an acute and chronic perspective. Expert Rev Pharmacoecon Outcomes Res 2009 9 : 423 433.
17. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 358 : 1431 1443.
18. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 359 : 1343 1356.
19. Viljoen A, Wierzbicki AS. Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract 2008 62 : 518 520.
20. Wierzbicki AS. Muddy waters: more stormy SEAS for ezetimibe. Int J Clin Pract 2008 62 : 1470 1473.
21. Penning-van Beest FJ, Termorshuizen F, Goettsch WG et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007 28 : 154 159.